Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
NCT ID: NCT06211166
Last Updated: 2024-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2024-01-08
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse
NCT06000306
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
NCT06569095
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
NCT06294678
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
NCT06294691
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
NCT05335226
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute Leukemia
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Digital PCR
digital Polymerase Chain Reaction (dPCR)
Quantitative PCR
Real-time Polymerase Chain Reaction (real-time PCR)
MFC
Multicolor Flow Cytometry
MDS or MDS/MPN
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and other subtypes of Myelodysplastic/Myeloproliferative Neoplasm
Digital PCR
digital Polymerase Chain Reaction (dPCR)
Quantitative PCR
Real-time Polymerase Chain Reaction (real-time PCR)
MFC
Multicolor Flow Cytometry
CML
Chronic Myeloid Leukemia
Digital PCR
digital Polymerase Chain Reaction (dPCR)
Quantitative PCR
Real-time Polymerase Chain Reaction (real-time PCR)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Digital PCR
digital Polymerase Chain Reaction (dPCR)
Quantitative PCR
Real-time Polymerase Chain Reaction (real-time PCR)
MFC
Multicolor Flow Cytometry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Neutrophil engraftment
* Received at least one MRD monitoring by digital PCR after HSCT
Exclusion Criteria
* Patients only with mutations in DNMT3A, TET2, and ASXL1 ("DTA mutations") or only germline mutations
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiao-Jun Huang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiao-jun Huang, M.D
Role: PRINCIPAL_INVESTIGATOR
Peking University People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021PHA154-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.